GLP-1 Eligibility: Clinical Criteria & Biomarker Considerations

Last reviewed: June 2, 2026

Last updated: June 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists are FDA-approved medications for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or higher, or those with BMI ≥27 kg/m² plus at least one weight-related condition such as hypertension, type 2 diabetes, or cardiovascular disease. However, eligibility extends beyond BMI cutoffs and requires careful assessment of medical history, medications, contraindications, and individual metabolic factors.

Many patients wonder whether they are a suitable candidate for GLP-1 therapy. Beyond standard clinical criteria, emerging biomarker and genetic insights may provide additional context for understanding how your body might respond to this class of medication. A comprehensive eligibility conversation with your healthcare provider should factor in both traditional medical indicators and, increasingly, personalized metabolic and genetic predisposition data.

Clinical Eligibility Criteria: Who Qualifies for GLP-1 Therapy

The FDA-approved indications for GLP-1 agonists include chronic weight management in adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity. Additionally, certain GLP-1 medications carry separate approvals for type 2 diabetes management. Your healthcare provider evaluates whether your weight and health profile align with these thresholds and whether the medication fits your clinical goals.

Eligibility is not determined by BMI alone. Providers also assess cardiovascular risk factors, metabolic syndrome indicators, insulin resistance markers, and baseline glycemic control. Patients with a family history of thyroid cancer, medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not use GLP-1 agonists due to theoretical safety risks, though these are rare.

Medical Contraindications and Safety Considerations

Absolute contraindications to GLP-1 therapy include personal or family history of medullary thyroid carcinoma, MEN 2, severe hypersensitivity, and active pancreatitis. Relative contraindications or caution factors include a history of gastroparesis, diabetic retinopathy, thyroid nodules, gallbladder disease, and severe renal or hepatic impairment. Your provider will review your full medical history, including prior adverse reactions to similar medications.

Safety Factor	Clinical Consideration
Absolute Contraindications	Personal/family history of medullary thyroid cancer, MEN 2 syndrome, or severe hypersensitivity to GLP-1 class
Gastrointestinal History	Severe gastroparesis, acute pancreatitis, or biliary disease may require caution or additional monitoring
Endocrine/Metabolic Status	Thyroid nodules, abnormal TSH, or concurrent thyroid medication use warrant baseline and ongoing assessment
Renal and Hepatic Function	Severe impairment (eGFR <15 or advanced cirrhosis) may limit drug clearance; dose adjustments or monitoring needed

Metabolic and Biomarker Context: Beyond Standard Screening

Standard eligibility screening focuses on weight, BMI, comorbidities, and safety contraindications. Increasingly, providers recognize that metabolic markers—such as fasting glucose, HbA1c, insulin resistance (HOMA-IR), lipid profile, and inflammatory markers—can provide additional insight into whether a patient may benefit from GLP-1 therapy and how their body might respond.

Genetic predispositions in peptide signaling pathways may also inform response variability. Variants in the GLP1R gene, GIPR gene, FTO gene, and MC4R gene are associated with differences in appetite regulation, satiety responsiveness, and metabolic rate. Understanding your genetic predisposition profile does not determine eligibility, but it may contextualize expected response patterns and help your provider tailor therapy.

The Role of Genetic Predisposition Mapping in Personalized Treatment Planning

While meeting clinical eligibility criteria means you qualify for GLP-1 therapy, your individual response and optimal dosing strategy may vary. Genetic predisposition testing examines variants in key appetite and metabolic genes—such as the GLP1R rs6923761 variant, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—that may be associated with differences in GLP-1 responsiveness and hunger regulation.

This genetic information should be interpreted by a qualified healthcare provider alongside your clinical history, metabolic markers, and treatment goals. Genetic predisposition testing can support a more personalized conversation about expected outcomes and optimal therapy duration, but it does not guarantee a specific medication response or predict individual safety.

How PlexusDx Supports a More Personalized Approach

At PlexusDx, we recognize that eligibility and personalization are interconnected. After confirming you meet baseline clinical criteria with your provider, our Precision Peptide Genetic Test may help provide context about your genetic predispositions in peptide signaling pathways—specifically variants in GLP1R, GIPR, FTO, and MC4R genes that influence appetite regulation and metabolic response patterns. This information can support a more informed conversation with your healthcare provider about therapy fit and response expectations.

The Precision Peptide Genetic Test reveals predispositions in peptide genetic pathways, not pharmacogenomic drug metabolism. It does not predict exact medication response or guarantee outcomes. Instead, it offers insight into biological factors that may influence how your body regulates appetite and satiety, helping contextualize why certain GLP-1 dosing strategies or combination approaches might be considered for your specific profile.

PlexusDx compounded GLP-1 options—including compounded semaglutide injection, oral semaglutide, compounded tirzepatide injection, and oral tirzepatide—are available at flat monthly rates across commitment tiers, so your dose can increase as clinically needed without your cost changing. After your first month of treatment, the Precision Peptide Genetic Test ($99 add-on) can help both you and your provider understand potential metabolic pathways relevant to your treatment response, supporting more targeted adjustments.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.